Bunge Global has just passed through its May 20 earnings release, and options traders wasted no time turning more cautious even as the Street's bull case remains structurally intact.
The sharpest move this week is in options sentiment. The put/call ratio jumped to 0.31 on May 19 — two standard deviations above its 20-day average of 0.27 — marking the most defensive options positioning Bunge has seen since early April. That's a notable shift for a stock that spent most of the past month with the PCR hugging the low end of its range near 0.24-0.25. The options market is pricing in more hedging demand, even with the PCR still well below its 52-week high of 1.23. The caution is real but not extreme.
Short interest tells a different story. Bears have been rebuilding modestly — SI climbed 8.1% on the week to 2.9% of the free float, reversing a quiet April in which short positioning had drifted lower from roughly 5.8 million shares. That's a low absolute level, and the borrow market reflects no real pressure: cost to borrow runs at just 0.46% annualised, barely changed, and availability is wide open at 1,746% of existing short interest. With over 102 million shares available to borrow relative to 5.7 million shorted, there is no lending constraint here. The week's SI pickup looks tactical rather than structural.
The Street remains firmly aligned to the upside. Barclays lifted its target to $150 on April 30, and across the past several months every notable analyst action — from JPMorgan, Morgan Stanley, BMO, and UBS — has been a raise with no cuts. The consensus mean target of $142 leaves about 16% above the current $122.26, a gap that has widened as the stock slipped 3.1% on the week. Factor scores paint a mixed picture: the dividend score ranks in the 67th percentile, momentum and value are more subdued, and the EV/EBITDA multiple has compressed roughly 8% over 30 days to 9.4x, while the P/E has moved lower too. The bull case — biofuel demand clarity, Viterra integration scale, improving crush margins — remains the narrative. Bears point to declining Agribusiness EBIT and softer Milling and Refined Oils results quarter-over-quarter.
Ownership is concentrated and stable. Glencore holds 16.9% and made no change last quarter. Canada Pension Plan Investment Board holds 13.5%, also unchanged. Capital Research added 3.6 million shares to bring its stake to 10.7% — the most notable institutional move in the recent window. British Columbia Investment Management built a position of nearly 4.6 million shares from close to zero, a material new entry. Broader passive holders — Vanguard, BlackRock, State Street — are each nudging positions incrementally higher. The ownership structure leans strategic and long-duration rather than hedge-fund-oriented, which helps explain why SI has remained persistently low.
The cluster of insider sells on May 15 — the board chair, independent directors, and several others all selling at $122.68 on the same date — is more mechanical than meaningful. The lot sizes are small (553 to 1,213 shares per person), the trade significance scores all register at 1 out of 10, and the net 90-day insider position is actually a modest net buy of 70,868 shares worth $8.9 million when the full window is considered. This reads as routine compensation-related selling, not a directional signal.
With Q1 earnings now in the rearview, the next watch point is whether the print clarifies the crush margin and biofuel demand trajectory that the bull case rests on — and whether that's enough to close the $20 gap between price and the Street consensus.
See the live data behind this article on ORTEX.
Open BG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
